Press Releases

Summary Toggle Chembio Receives $8.5 Million Commitment from Bio-Manguinhos to Purchase Components for Production of DPP® Assays in Brazil during 2018

Dec 5, 2017

Chembio Receives $4.2 Million in Accounts Receivable Payments from Bio-Manguinhos
Read more

Chembio Receives $8.5 Million Commitment from Bio-Manguinhos to Purchase Components for Production of DPP® Assays in Brazil during 2018 33.7 KB
Summary Toggle Chembio Diagnostics Awarded UNICEF Contract to Supply Point-of-Care DPP® Zika Assays and DPP® Micro Readers

Nov 28, 2017

MEDFORD, N.Y., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has been awarded a conditional Long Term Arrangement (LTA) from UNICEF for purchases of the Company's DPP ®
Read more

Chembio Diagnostics Awarded UNICEF Contract to Supply Point-of-Care DPP® Zika Assays and DPP® Micro Readers 87.5 KB
Summary Toggle Chembio Diagnostics Reports Third Quarter 2017 Financial Results

Nov 8, 2017

Conference Call and Webcast Today at 4:30 p.m. Eastern Time

Read more

Chembio Diagnostics Reports Third Quarter 2017 Financial Results 57.9 KB
Summary Toggle Chembio to Host Conference Call to Discuss Third Quarter 2017 Financial Results

Nov 1, 2017

Conference Call Scheduled for Wednesday, November 8th at 4:30 p.m. Eastern Time

Read more

Chembio to Host Conference Call to Discuss Third Quarter 2017 Financial Results 34.5 KB
Summary Toggle Chembio Announces Return of President and CEO John Sperzel

Oct 2, 2017

MEDFORD, N.Y., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that President and Chief Executive Officer, John Sperzel, has returned to work following a medical leave of absence.
Read more

Chembio Announces Return of President and CEO John Sperzel 31.5 KB
Summary Toggle Chembio Diagnostics Receives FDA Emergency Use Authorization for the First Rapid Zika IgM Test

Sep 28, 2017

MEDFORD, N.Y., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its DPP ® Zika
Read more

Chembio Diagnostics Receives FDA Emergency Use Authorization for the First Rapid Zika IgM Test 35.9 KB
Summary Toggle Chembio Diagnostics Announces Retirement of Chief Financial Officer

Aug 17, 2017

MEDFORD, N.Y., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that Richard J. Larkin, Executive Vice President and Chief Financial Officer (CFO), has informed the Company of his
Read more

Chembio Diagnostics Announces Retirement of Chief Financial Officer 31.4 KB
Summary Toggle Chembio Diagnostics Reports Second Quarter 2017 Financial Results

Aug 9, 2017

Conference Call and Webcast Today at 4:30 p.m. Eastern Time

Read more

Chembio Diagnostics Reports Second Quarter 2017 Financial Results 61 KB
Summary Toggle Chembio to Host Conference Call to Discuss Second Quarter 2017 Financial Results

Aug 3, 2017

Conference Call Scheduled for Wednesday, August 9th at 4:30 p.m. Eastern Time

Read more

Chembio to Host Conference Call to Discuss Second Quarter 2017 Financial Results 33.8 KB
Summary Toggle Gail S. Page Joins Chembio Diagnostics Board of Directors

Jul 6, 2017

Adds Additional Diagnostic Industry Leadership and Healthcare Expertise

Read more

Gail S. Page Joins Chembio Diagnostics Board of Directors 34.7 KB